01/08/2026
New analyses from the Phase 3 EPIDYS clinical trial are providing additional insight into Duvyzat’s potential benefits for boys with Duchenne muscular dystrophy (DMD). Read more here: https://bit.ly/4eQq8dN
According to researchers, patients receiving the therapy experienced functional gains regardless of the dose level they ultimately received. MRI findings also suggested slower muscle deterioration, including reduced fat infiltration and slower loss of functional muscle tissue.